Presented at #ESMO26:
Among patients with HER2-positive advanced breast cancer, the HER2-targeted bispecific antibody anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of 58.5%, as compared with 34.4% with standard therapy. Full phase 3 HEALER trial results: https://nej.md/4BcWlF3
Editorial: Targeting HER2 — A Triumph of Science https://nej.md/4Bh4GaF
@myESMO
1813 views · 5 likes · 3 reposts · 0 replies
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgAnbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.orgSource: NEJM · x.com